Patients with hairy cell leukaemia (HCL) have highly favourable outcomes after purine analogue therapy. However, most patients subsequently relapse and require re-treatment. A minority of patients develop purine analogue-refractory disease. Targeted therapies have improved outcomes for such patients. Recently, the BRAF V600E mutation was identified in most patients with classical HCL, resulting in constitutive mitogen-activated protein kinase pathway activation; impressive responses are achieved in heavily pre-treated patients with BRAF inhibition. The CD22-targeted immunoconjugate moxetumomab pasudotox and BTK inhibitor ibrutinib also achieve responses in relapsed and refractory patients. HCL variant and the IGHV4-34 molecular variant of HCL lack BRAF mutation and have inferior outcomes with standard purine analogue therapy. The addition of rituximab to purine analogues achieves very high rates of minimal residual disease-negative complete remission and improves outcomes for patients with HCL variant. Given the rarity of HCL, optimal integration of novel therapies into treatment algorithms will require well-designed, collaborative studies.
Named for the existence of numerous 'hairy' cytoplasmic surface projections, visible by light microscopy (Bouroncle et al, 1958) , classical hairy cell leukaemia (cHCL) was subsequently identified to have a characteristic immunophenotype by flow cytometry; this distinguishes it from diseases which, while morphologically similar, have distinct biology and clinical behaviour, such as hairy cell leukaemia variant (HCL-v) (Foucar et al, 2008) . More recently, the molecular pathogenesis of the cHCL was elucidated; with the exception of the IGHV4-34 molecular variant, virtually all cases of cHCL demonstrate a characteristic V600E point mutation in the BRAF gene, resulting in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway (Tiacci et al, 2011) . The existence of this molecular hallmark of disease is useful both diagnostically and therapeutically; high response rates to treatment with specific inhibitors of BRAF in patients with multiply relapsed cHCL have been noted in recent landmark studies .
Classical HCL represents one of the great success stories in modern oncology. The development of purine analoguebased therapy has resulted in the vast majority of patients achieving durable complete remission (CR) after treatment. Although not curative in all patients, most patients respond to re-treatment. The recent development of targeted therapies that are highly effective in relapsed disease has further improved outcomes, leading to patients having a similar life expectancy to appropriate age-matched controls (Else et al, 2009 ). However, the median age at diagnosis is 55 years and younger patients (<40 years of age) with HCL have a small, but significantly increased, mortality relative to controls (Rosenberg et al, 2014) . Therefore, opportunities to improve outcomes still exist. In addition to small molecule inhibitors of BRAF, several monoclonal antibodies, both naked and conjugated, targeting CD20 and CD22, which are highly expressed on cHCL cells, are being actively explored in clinical trials, as is the bruton tyrosine kinase (BTK) inhibitor, ibrutinib.
The availability of multiple active, targeted therapies in cHCL creates opportunities for novel strategies to be developed in both relapsed disease and in the first line setting. However, the generally excellent outcomes for patients after purine analogue-based therapy, particularly in the first line setting, makes evaluating these novel therapies challenging. Progression-free survival (PFS), particularly in the first-line setting, is an unrealistic endpoint for a comparative study, due to the requirement for prolonged follow-up in order to detect a difference. For this reason, minimal residual disease (MRD), which can be detected by multi-parameter flow cytometry in the bone marrow (BM) of most patients who achieve CR after initial purine analogue-based therapy for cHCL, can potentially be used for such comparative studies. However, data demonstrating its validity as a useful surrogate marker for PFS or survival is lacking. The precise role of MRD analysis in routine practice and, in particular, the role of consolidation therapy intended to eradicate MRD, is the subject of ongoing research efforts. The relative rarity of the disease mandates collaborative efforts if further meaningful trials demonstrating the role of the new strategies are to be conducted.
Molecular pathogenesis of the disease
The BRAF V600E mutation is the molecular hallmark of cHCL (Tiacci et al, 2011) . Tiacci et al sequenced 48 patients with cHCL (one with whole exome sequencing and the remainder with targeted sequencing for the BRAF mutation); all were demonstrated to carry BRAF V600E. Thirty-eight cases of morphologically similar diseases, such as splenic marginal zone lymphoma and unclassifiable B-cell lymphomas, were all negative for BRAF mutation. They also demonstrated phosphorylation of MEK and ERK, which are downstream targets of BRAF, indicating constitutive activation of the MAPK pathway. Furthermore, specific inhibition of BRAF resulted in marked reduction in MEK and ERK phosphorylation, indicating the functional importance of the BRAF mutation (Tiacci et al, 2011) . Subsequently, elegant work from the same group (Pettirossi et al, 2015) demonstrated in both in vitro assays and in vivo that exposure to BRAF inhibition dramatically reversed the characteristic phenotypic and molecular signature of cHCL cells; specifically, dose-dependent MEK and ERK dephosphorylation was seen. Gene expression profiling demonstrated marked changes in the transcriptional profile, including down-regulation of targets of the BRAF-MEK-ERK pathway and genes encoding proteins such as CD25. These changes coincided with loss of the hairy cytoplasmic projections seen by light microscopy. Subsequently, cells underwent apoptosis, which could be partially rescued by stromal co-culture. Similar experiments conducted on cells purified from patients with hairy cell-like disease (such as HCL-v) demonstrated no morphological changes or induction of apoptosis, indicating that these effects were produced by BRAF inhibition, not an off-target effect of the drug (Pettirossi et al, 2015) .
Taken together, this is strong evidence for the central role that the BRAF V600E mutation plays in disease pathogenesis in cHCL and validates BRAF as a specific target in cHCL. Occasional cases of cHCL do lack BRAF V600E mutation. Many, but not all of these, utilize IGHV4-34 and/or do not have somatic hypermutation of the immunoglobulin heavy chain variable region gene (IGHV); they are commonly referred to as the IGHV4-34 molecular variant (Xi et al, 2012) . While IGHV4-34 utilization is most common in HCLv, it is present in up to 10% of cases classified by flow cytometry as cHCL. The clinical course in these patients is aggressive, with high white cell count at presentation, suboptimal response to purine analogue therapy, and inferior survival (Arons et al, 2009 ). IGHV4-34 molecular variant cases are universally BRAF mutation negative (Xi et al, 2012) and represent a molecularly distinct disease. A high proportion of both HCL-v and IGHV4-34 variant cases demonstrate MAP2K1 mutations, which result in constitutive MEK1 phosphorylation and downstream ERK activation (Waterfall et al, 2014) .
Clinical presentation and diagnosis
Classical HCL is uncommon, with an incidence of 600-800 new cases/year in the U.S. and representing approximately 2% of all lymphoid malignancies (Foucar et al, 2008) . It has a striking male predominance, with a male:female ratio of approximately 5:1 (Else et al, 2005) . The median age at diagnosis is approximately 50 years (Foucar et al, 2008) .
The majority of patients present with pancytopenia. Monocytopenia is characteristic. Circulating hairy cells in the blood are generally sparse and may be absent (Foucar et al, 2008) : if present, they are medium-sized cells, have bean-shaped nuclei without nucleoli and demonstrate abundant cytoplasm with characteristic 'hairy' cytoplasmic projections (Sharpe & Bethel, 2006) . While the haematological abnormalities may be an isolated, incidental finding, many patients have multifactorial fatigue, splenomegaly with associated left upper quadrant discomfort, fever and systemic symptoms and may suffer consequences related to cytopenias, such as infection.
Flow cytometry in the blood or BM aspirate demonstrates a characteristic immunophenotype. Hairy cells express bright, monotypic surface immunoglobulin, CD19, bright CD20, CD22 and CD11c, in addition to CD25, CD103, CD123 and FMC7. Weak expression of cyclin D1 is usual. Most cases lack CD10 and CD5 expression (Foucar et al, 2008) . CD200 is also a specific marker, being highly expressed in cHCL but not in HCL-v or other morphologically similar lymphoproliferative disorders, such as marginal zone lymphoma. Although CD200 is also expressed in chronic lymphocytic leukaemia (CLL), the immunophenotype and morphology in CLL are sufficiently different from cHCL that diagnostic confusion is unlikely to arise between these two entities.
An increase in BM reticulin fibrosis may result in a 'dry tap' (Foucar et al, 2008) ; thus, often, limited material is available from the aspirate. BM biopsy demonstrates an interstitial lymphoid infiltrate; the abundant cytoplasm results in widely spaced nuclei, giving a characteristic 'fried egg' appearance. Immunohistochemistry for Annexin A1 is the most specific for diagnosis of cHCL as it is not expressed in other B-cell malignancies (Falini et al, 2004) , but it must be compared to a pan B-cell marker, such as CD19 or CD20, as it is also expressed by myeloid cells and some T-cells (Foucar et al, 2008) . DBA.44 expression is also often used. Cytochemistry for tartrate-resistant acid phosphatase has been used in the past, but due to its technical challenges, has largely been replaced by immunohistochemistry (Sharpe & Bethel, 2006; Foucar et al, 2008) .
from HCL-v and other similar disorders. The key distinguishing features between cHCL and HCL-v are presented in Table I .
Evaluation of response to therapy
Consensus criteria for CR in HCL have not been updated since 1987 (Anonymous, 1987) . CR was defined when all the following criteria were fulfilled: (i) absence of hairy cells in the peripheral blood and BM, by morphology; (ii) normalization of peripheral blood counts [haemoglobin (Hb) ≥120 g/l; white blood cells, ≥3Á0 9 10 9 /l; neutrophils, ≥1Á5 9 10 9 /l; platelets 100 9 10 9 /l]; (iii) regression to normal of all palpable organomegalies; and (iv) absence of constitutional symptoms. We define CR as the absence of hairy cells on BM aspirate smears or the presence of less than 1% atypical cells in BM and blood and the disappearance of all evidence of HCL on physical examination (Ravandi et al, 2006) . Achievement of CR requires an absolute neutrophil count (ANC) of at least 1Á5 9 10 9 /l; Hb at least 120 g/l (at least 110 g/l for women); and platelet count at least 100 9 10 9 /l without growth factor or transfusion support. CR with residual disease (CR-RD) is defined as for CR but with persistence of 1-5% hairy cells in the marrow (but no circulating hairy cells). Partial response (PR) is defined as: (i) meeting the peripheral blood criteria for CR/CR-RD but more than 5% residual hairy cells in the marrow, or (ii) at least 50% improvement or correction of at least one cytopenia without a decrease in any other cell count, reduction in palpable abnormalities on physical examination by at least 50%, and reduction in circulating or BM hairy cells by at least 50%. Of note, eradication of MRD by sensitive immunohistochemistry, flow-cytometric or molecular testing is not required for the definition of CR. Achievement of CR, rather than PR, appears to correlate with longer PFS (Saven et al, 1998; Goodman et al, 2003; Else et al, 2009) . Patients in CR at 5 years have only c. 25% risk of relapse at 15 years (Else et al, 2009 ).
Treatment

Indications for therapy
Classical HCL has an indolent disease course. Some patients survive for many years without receiving therapy; others do not require further therapy for many years, despite the persistence of residual morphological evidence of disease after initial treatment (Sigal et al, 2010) . As a result, some patients may be initially observed, without specific therapy. We generally initiate treatment when patients have significant cytopenias (Hb < 110 g/l, ANC < 1Á0 9 10 9 /l and/or platelets <100 9 10 9 /l), if patients have massive or symptomatic splenomegaly, constitutional symptoms, such as fever or night sweats, or if patients have experienced infections.
First line therapy
Historic therapeutic modalities Splenectomy. Until the advent of interferon-a, splenectomy was performed as a palliative procedure, normalizing peripheral blood counts in approximately 70% of patients, despite not leading to morphological BM remissions (Jansen & Hermans, 1981; Golomb & Vardiman, 1983; Van Norman et al, 1986) . Progression occurs in 45% of cases within 5 years (Magee et al, 1985) and there is the potential for both morbidity and mortality; given the availability of effective systemic therapy, the procedure is now rarely performed. Specific situations where splenectomy may be considered are after non-traumatic rupture, which is a very rare (Gedik et al, 2008) or for truly refractory disease (Habermann & Rai, 2011) in the latter case, we would exhaust clinical trial options of systemic therapy prior to resorting to splenectomy. Splenectomy has been used to treat pregnant women to delay chemotherapy administration; HCL in pregnant women requiring treatment is a rare situation; management decisions are complex and reviewed elsewhere (Daver et al, 2013) .
Interferon-a. Interferon-a, at doses ranging from 3 million units, daily to 2 million units, 3 times weekly, achieves high response rates, but the majority are PRs. Median failure-free survival is short (10-25 months) (Ratain et al, 1987 Golomb et al, 1988; Berman et al, 1990 ) and the therapy is associated with significant toxicity, including flu-like symptoms, fatigue and depression. The recent availability of the more tolerable PEGylated forms of interferon-a provides an option for exceptional cases when nucleoside analogues cannot be used.
Purine nucleoside analogues
Purine nucleoside analogue (PA) monotherapy is the mainstay of treatment for cHCL. Deoxygenated adenosine triphosphate (dATP) is a key component of DNA synthesis. In all cells, there is a dynamic equilibrium between the production of dATP from unphosphorylated adenosine (deoxyadenosine; dAdo), via deoxyadenosine monophosphate (dAMP) and deoxyadenosine diphosphate (dADP). The rate limiting step in the production of dATP from dAdo is the conversion of dAdo to dAMP by deoxycytidine kinase (dCK) (Pettitt, 2003) . The ratelimiting step in the reverse process is the dephosphorylation of dAMP by 5 0 -nucleotidase. In lymphoid cells, there is significantly greater activity of dCK, favouring the production of dATP. dAdo can also be converted into deoxyinosine by adenosine deaminase (ADA), deficiency of which results in a form of severe combined immune deficiency, characterized by nearabsence of lymphocytes. The purine analogues pentostatin and cladribine both result in accumulation of intracellular dATP: pentostatin is a specific inhibitor of ADA, while cladribine is a dAdo analogue that resists deamination by ADA. Accumulation of dATP results in DNA strand breaks, inhibition of DNA repair and apoptosis; there is selectivity for lymphoid cells due to the relative deficiency of 5 0 nucleotidase in lymphoid cells, which results in accumulation of triphosphorylated purine analogue and incorporation into DNA (Pettitt, 2003) .
Cladribine monotherapy. Monotherapy with cladribine is highly effective as initial therapy of cHCL, with an overall response rate of 75-100% and a CR rate of 72-98%, after a single course of therapy. Numerous different routes and schedules of administration have been reported, with broadly comparable results (Table II) . The most frequently utilized regimens include: 0Á14 mg/kg/day given as a 2-h IV infusion for 5 consecutive days (Zinzani et al, 2004) , 5Á6 mg/m 2 /day given as a 2-h IV infusion for 5 consecutive days (Ravandi et al, 2011) , which is preferred at our institution, 0Á1 mg/kg/ day given as a continuous IV infusion (CIVI) for 7 consecutive days Saven et al, 1998; Goodman et al, 2003; Jehn et al, 2004; Chadha et al, 2005) and weekly administration of 0Á12-0Á15 mg/kg, for 5-6 consecutive weeks (Lauria et al, 1997; Robak et al, 1999; Zinzani et al, 2004) . The latter regimen was evaluated in an attempt to reduce the rates of severe neutropenia and infections (Lauria et al, 1997) . However, a randomized study comparing 5 consecutive days of 0Á12 mg/kg/day and 6 consecutive weeks of 0Á15 mg/kg demonstrated similar response rates, PFS, survival and grade 3-4 infections (Robak et al, 2007) . There were 3 early deaths, 2 in the daily and 1 in the weekly arm of the study (Robak et al, 2007) . Subcutaneous (SQ) administration has also been utilized; area under the curve (AUC) of drug exposure was similar for SQ dosing compared to 7 day CIVI or IV bolus dosing (Juliusson et al, 1995) . The overall CR rate after 1 course of daily SQ administration for 7 days was 75%. Interestingly, patients with higher cladribine AUC after SQ dosing had a higher CR rate. Median PFS in long-term follow-up cohorts ranges from 8 to 12 years (Goodman et al, 2003; Jehn et al, 2004; Zinzani et al, 2004; Chadha et al, 2005; Else et al, 2009) with overall survival at >10 years of 79-96% (Goodman et al, 2003; Jehn et al, 2004; Zinzani et al, 2004; Chadha et al, 2005) .
Pentostatin monotherapy. Similarly excellent results are seen with pentostatin monotherapy in the first line setting (Table III) . Pentostatin was the first agent shown to produce high numbers of CRs in patients with HCL (Kraut et al, 1989) and was subsequently demonstrated to be superior to interferon-a in a randomized study (Grever et al, 1995) . Numerous series have evaluated pentostatin, given either first line or after failure of interferon-a, in a variety of different doses and schedules, most commonly 4 mg/m 2 , IV, every 2 weeks until maximum response (Kraut et al, 1989; Grever et al, 1995; Ribeiro et al, 1999; Flinn et al, 2000; Rafel et al, 2000; Maloisel et al, 2003; Else et al, 2009) ; the overall response rate (ORR) ranges from 79% to 100%, with CR rate of 44-89%. In long-term follow-up studies, event-free survival at 10 years ranges from 58% to 69%, in responding patients (Flinn et al, 2000; Maloisel et al, 2003) .
Pentostatin versus cladribine. There has been no direct, randomized comparison between the two treatment approaches, but long-term results of the two approaches appear to be similar. Else et al (2005) reported long-term follow-up of a non-randomized, single-centre comparison which demonstrated a similar median PFS of approximately 10Á5 years for patients receiving cladribine in various schedules or pentostatin 4 mg/m 2 every 2 weeks, until maximum response.
Median relapse-free survival (RFS; censored for deaths in remission) was 16 years in both arms and was markedly longer in patients who achieved CR initially.
It has been suggested that initial therapy with pentostatin may reduce the incidence of severe myelosuppression and febrile neutropenia, particularly as the interrupted schedule allows dose delays and/or reductions in the event of significant neutropenia. However, this must be balanced against the inconvenience of prolonged administration and clinic visits, with many patients needing 10 or more infusions every 2 weeks to achieve maximal response, compared to a single course of 5-7 days with cladribine (Grever, 2010) .
A randomized comparison is unlikely to be performed and, given the generally similar long-term results in multiple studies, it is not a research priority in HCL. Either approach appears reasonable for first-line or subsequent therapy of HCL and we recommend that institution/clinician experience dictate this choice.
The role of post-treatment evaluation of MRD
Despite the very high initial CR rate with purine analogue therapy, eventual relapse occurs in many patients; no longterm follow-up study has demonstrated a plateau on the PFS/RFS curves (Else et al, 2009) . This is consistent with the observation that MRD can be detected in most patients otherwise determined to be in CR after purine analogue monotherapy, using more sensitive techniques. MRD can be detected in patients in morphological CR using immunohistochemistry for CD45RO, CD20 and DBA.44 (Wheaton et al, 1996) or using more sensitive methods, such as multiparameter flow cytometry (MFC) or polymerase chain reaction (PCR) using consensus or clone-specific primers for the IGH gene (Sausville et al, 2003; Arons et al, 2006; Ravandi et al, 2006) . MFC detects residual HCL in the majority of cases after cladribine monotherapy; only 11/59 treatment-na€ ıve patients in our recently updated experience (Chihara et al, 2016) were MRD-negative by flow after initial treatment. MFC is significantly more sensitive than PCR using consensus primers for the detection of MRD, but significantly less sensitive than PCR using clone-specific primers (Arons et al, 2006) . However, PCR using clone-specific primers is labourintensive and not widely available.
Evaluation of MRD post-treatment in haematological malignancies serves several potential purposes: (i) it may give more accurate information concerning the likelihood and timing of relapse; (ii) if the former is true, this may allow We have demonstrated that MRD detected by MFC, with a sensitivity of 0Á05-0Á003% (Ravandi et al, 2011) can be eradicated in the majority of patients with 8 doses of weekly rituximab after cladribine (Chihara et al, 2016) . However, the generally prolonged remissions after treatment and the indolent nature of HCL mean that prolonged follow-up will be required to determine whether such eradication of MRD translates into improved PFS and other survival outcomes. Therefore, while we routinely evaluate post-treatment MRD using flow cytometry in our patients and it seems likely that increasing depth of remission (as determined by MRD-negativity) will translate to improved outcomes, we cannot currently recommend any treatment decisions be made on the basis of this information.
Biomarkers which correlate with response
CD22 is expressed at high levels on the surface of HCL cells (Rawstron et al, 2006) . Soluble CD22 (sCD22) can be detected in plasma and correlates with pre-and posttreatment disease burden, and response to therapy. Patients who achieve CR have levels post-treatment within the normal range, while those with PR have levels above the upper limit of normal (Matsushita et al, 2008) . Correlation of sCD22 levels with MRD has yet to be performed.
In our most recent study of cladribine plus rituximab in first-line and first relapse of cHCL and HCL-v, we analysed serial levels of soluble IL-2 receptor (IL2RA, also termed CD25) in plasma and demonstrated similar findings: levels were markedly elevated pre-treatment, decreased during cladribine therapy and decreased further after treatment with rituximab (Ravandi et al, 2011) .
The precise role of monitoring of soluble factors in HCL remains to be established.
Factors at baseline associated with outcome
Several studies have shown that leucocytosis and marked splenomegaly (Saven et al, 1998; Goodman et al, 2003; Forconi et al, 2009 ) and CD25 negativity (Hoffman et al, 1997) predict shorter time to treatment failure/PFS and survivalthis is probably attributable to the fact that many such patients have the IGHV4-34 molecular variant of cHCL, cHCL with unmutated IGHV (Forconi et al, 2009 ) or HCLv. Response rates and PFS/survival in these historical series need to be evaluated with the knowledge that many such patients were included prior to the availability of molecular tests of cHCL. Several other variables have been shown to be associated with poorer outcomes, including older age, lower Hb level or platelet count, splenectomy, splenomegaly, lymphadenopathy, leucopenia, leucocytosis, previous treatment, shorter time from diagnosis to treatment and lower performance status (Cheson et al, 1998; Saven et al, 1998; Flinn et al, 2000; Rafel et al, 2000; Goodman et al, 2003; Maloisel et al, 2003) .
One series demonstrated that unmutated IGHV (>98% homology to germline), present in 10% of cHCL cases, also appears to be a high-risk feature ). Somatic hypermutation is significantly more frequent in cHCL than HCL-v (83% vs. 46%) (Arons et al, 2011) , and in IGHV4-34 cHCL. However, only 1/6 of the unmutated patients had IGHV4-34 and all were phenotypically cHCL. Therefore, the unmutated genotype appears to be a high-risk feature, independent of specific IGHV utilization and characterization as HCL-v.
Toxicity of purine analogue therapy and supportive care
Other cancers
There is conflicting data concerning the risk of other cancers in patients with HCL. The two largest studies of cladribine therapy showed a small but increased risk (hazard ratio 1Á88-2Á03) of other cancers (Saven et al, 1998; Goodman et al, 2003) ; the most common tumours seen reflect the frequencies seen in the general population (adenocarcinoma of colon, prostate and non-melanoma skin cell cancer). Longterm follow-up studies of patients treated with pentostatin have not shown an excess of other cancers (Flinn et al, 2000; Maloisel et al, 2003) ; however, there appears to be an increased incidence of secondary cancers in patients with HCL in large, population-based studies. Hodgkin lymphoma, non-Hodgkin lymphoma and thyroid cancer appeared particularly increased (Hisada et al, 2007) . Of note, unlike in CLL, there does not appear to be a noticeable increase in myelodysplasia or acute myeloblastic leukaemia.
Myelosuppression, lymphopenia and infections
Purine analogues predictably cause profound and prolonged neutropenia in the majority of patients, with febrile neutropenia in 30-50% of patients (Kraut, 2011) . Saven et al (1999) conducted a phase II clinical trial utilizing filgrastim priming, followed by post-treatment filgrastim therapy and compared the results to a historical control group treated without filgrastim; although median ANC nadir increased from 0Á29 to 0Á53 9 10 9 /l and median number of days to an ANC >1Á0 9 10 9 /l decreased from 22 to 9, there was no benefit in clinical outcomes (percentage of febrile patients, frequency of admissions and number of febrile days) . We therefore do not routinely give filgrastim prophylaxis during treatment, with the exception of elderly patients, as per American Society of Clinical Oncology guidelines (Smith et al, 2015) . Both cladribine and pentostatin cause profound and prolonged T-cell depletion; absolute CD4 + and CD8 + counts are generally <0Á2 9 10 9 /l for at least 6 months and median time to recovery to the normal range is 54 months after pentostatin (Seymour et al, 1997) and 40 months after cladribine (Seymour et al, 1994) . Despite this, opportunistic infections in the major reported series are rare, apart from occasional cases of zoster infection (Saven et al, 1998) and infection during long-term follow-up is very rare (Flinn et al, 2000; Else et al, 2005; Huynh et al, 2009 ). We do not routinely prescribe pneumocystis prophylaxis. Acyclovir or valacyclovir prophylaxis for herpes virus infection is given according to physician preference. Overall, infectious mortality is extremely low. In aggregate, across 5 large studies, 6 of 1444 (0Á4%) patients died as a result of infection (Kraut, 2011) .
Patients who present with pancytopenia and sepsis represent a specific challenge. In general, we attempt to treat the infection first, with broad-spectrum antibiotics. Once the patient is stable, we will initiate chemotherapy with cladribine. After completion of chemotherapy, in this situation, we give growth factor support to accelerate neutrophil recovery.
Improving on initial purine analogue monotherapy in the first line setting
Addition of rituximab to cladribine
Most patients treated with purine analogues as first-line treatment for HCL will have detectable MRD post-treatment and will eventually relapse. Sequential therapy with 8 doses of rituximab 375 mg/m 2 , weekly, after completion of cladribine, achieved a CR rate of 100% and increased MRD-negativity from 14% to 74% (including 76% of untreated patients and 64% of patients in first relapse) (Chihara et al, 2016) . Five-year failure-free survival (FFS) was 95%. Longer-term follow-up will be required to determine whether this translates into improved FFS for the first-line patients. Although we believe this strategy has the potential to minimize relapse in HCL, the addition of rituximab to cladribine as first line treatment for cHCL should only be performed currently as part of a clinical trial. HCL-v needs a specific mention as it responds poorly to cladribine monotherapy, with a CR rate of 8% and ORR of 44% in the largest reported studies (Robak et al, 1999; Tetreault et al, 1999; Matutes et al, 2001; Palomera et al, 2002; Machii et al, 2005; Arons et al, 2009) . It also responds poorly to therapy with pentostatin (Matutes et al, 2001) . The combination of cladribine and immediate rituximab (8 weekly doses of 375 mg/m 2 ) achieved CR in 9 of 10 patients, 8 of whom were MRD negative by flow cytometry in BM . Treatment was well tolerated, other than frequent infusion reactions. Despite a high incidence of neutropenia, only 1/10 patients developed febrile neutropenia and, although there was rapid development of thrombocytopenia early in therapy, this was not severe enough to cause bleeding or require platelet transfusions. In our experience with cladribine followed by rituximab, 6/7 (86%) achieved CR and 5-year FFS was 64Á3%; two relapses were seen (at 19 and 96 months post-initiation of therapy) (Chihara et al, 2016) . Concomitant administration of rituximab with fludarabine (another purine analogue) has been shown to be more effective than sequential therapy in CLL patients (Byrd et al, 2003) . This raises the question of whether such a strategy would also be more effective in patients with HCL. An ongoing clinical trial is attempting to determine whether the sequential or simultaneous administration of rituximab with purine analogues in HCL is optimal (NCT00781235).
In the future, we may see novel strategies (e.g. rituximab + BRAF inhibitor compared with purine analogues + rituximab). It is, however, very likely that first line therapy will continue to be with nucleoside analogues with or without rituximab, as indefinite therapy with oral agents, such as vemurafenib or ibrutinib that are costly and associated with significant potential toxicities, cannot be justified given the excellent results of purine analogue monotherapy or purine analogues combined with rituximab.
Treatment of relapsed disease
Purine analogues
Re-treatment with purine analogue therapy achieves second CR in up to 80% of patients as summarized in Table IV ; (Saven et al, 1998; Goodman et al, 2003; Maloisel et al, 2003; Chadha et al, 2005; Else et al, 2009; Rosenberg et al, 2014 ) the choice of cladribine versus pentostatin does not appear to have a significant impact (Else et al, 2005) . Although overall response rates in 2nd and 3rd line therapy remain close to 100%, there is progressive reduction of DFS and CR rates (Tables IV, V) . In one series, shorter duration of first remission was the only variable associated with failure to attain CR with second-line therapy and achievement of 2nd CR was the only factor significantly associated with longer 2nd RFS (Else et al, 2009) . There is also the potential concern of cumulative immunosuppression due to profound CD4 + T-cell depletion. Nonetheless, re-treatment with purine analogues remains as the standard-of-care.
Rituximab monotherapy
The anti-CD20 monoclonal antibody, rituximab, has singleagent activity in relapsed/refractory HCL, with ORR ranging from of 26% to 80% (Hagberg & Lundholm, 2001; Nieva et al, 2003; Thomas et al, 2003) . Responses can be durable; in our experience, 58% of responding patients had not progressed at a median follow-up of 32 months. Rituximab has also been evaluated for its potential to eradicate MRD after initial treatment with a purine analogue (Cervetti et al, 2004 (Cervetti et al, , 2008 Ravandi et al, 2006 Ravandi et al, , 2011 Chihara et al, 2016) .
Purine analogues combined with rituximab
There is relatively limited data on the use of purine analogue therapy combined with rituximab in the treatment of relapse after initial purine analogue therapy. We have treated 14 patients with relapse after 1 prior course of therapy (cladribine n = 12, pentostatin n = 1 or rituximab monotherapy, n = 1) with cladribine followed by 8 weekly doses of rituximab; CR rate was 100%. Of note, after a median follow-up of 5 years, no patient has relapsed and FFS after 2nd line cladribine + rituximab was significantly longer (P = 0Á004) than after initial monotherapy (where median FFS was 6 years) (Chihara et al, 2016) . Similarly, The Royal Marsden Hospital group have shown impressive CR rates (11/12 patients) (Else et al, 2007 (Else et al, , 2009 ) in a heavily pre-treated population with either concurrent or sequential purine analogue therapy + rituximab. All of the complete responders became MRD-negative after treatment (evaluated by immunohistochemistry). Chihara et al (2016) 2-CdA 5Á6 mg/m 2 /day 9 5 days followed by 375 mg/m 2 rituximab 9 8 weekly doses 14 100 100 5-year FFS 100%. Kreitman et al (2013) 10 with HCL-v, 8 previously treated 100 90 NR 90% FFS at 30 months 2-CdA, cladribine; CIVI, continuous intravenous infusion (0Á1 mg/kg/day 9 7 days, unless stated); CR, complete remission; ORR, overall response rate; FFS, failure-free survival; mDOR, median duration of response; HCL-v, hairy cell leukaemia variant; NR, not reported; mPFS, median progression-free survival.
BRAF inhibition
The critical importance of constitutive BRAF-MEK-ERK signalling, induced by the BRAF V600E mutation in cHCL (Tiacci et al, 2011 ) has been discussed above. This discovery led to 2 separate phase II studies being conducted with the BRAF inhibitor, vemurafenib. This drug is approved for the treatment of metastatic melanoma, which also carries the canonical BRAF V600E mutation. The patient populations were either heavily pre-treated or had early-relapse after PA therapy. In the Italian study, 6 patients had not responded to or relapsed within 1 year of PA therapy and 20 had either relapsed within 1-2 years of the first course or within 4 years of the second course of PA therapy . In the US trial, most patients were enrolled on the basis of having received 3 or more prior courses of PA therapy . A total of 54% of patients in the Italian study and 41% in the US study were refractory to their most recent prior therapy. Patients received vemurafenib for 12-20 weeks in total and could be re-treated at progression. ORR and complete response rate was 96/100% and 35/42%, respectively. In the Italian study, which had longer follow-up, median RFS was 9 months; in the US study, 1 year PFS was 73%. Some patients responded to re-treatment at relapse. Molecular mechanisms of resistance have not been well characterized for most patients on the studies; however, one patient in the US study was found to have sub-clonal KRAS mutation, which results in MEK-ERK activation, and is a well-described resistance mechanism to BRAF inhibition in melanoma (Nazarian et al, 2010) . In addition, residual ERK phosphorylation was noted by immunohistochemistry in approximately half the patients on the Italian study and appeared to correlate with poorer PFS. Toxicity was generally manageable and was similar to that seen in studies of melanoma patients, especially rash, photosensitivity, palmar/plantar fibrosis, warts and arthralgias. Dose reduction was required in 50-58%. Seven patients developed skin cancer (6 non-melanoma, one superficial spreading melanoma) Falini et al, 2016) . Clearly, these are impressive results in a highly refractory population and we would expect to see longer response duration in patients treated at earlier disease stages. Nevertheless, there is room for improvement. In melanoma with BRAF V600E, resistance predictably develops after a median of 6-7 months, often due to the development of NRAS mutations, which provide an alternative mechanism of MEK-ERK activation (Nazarian et al, 2010) . Additionally, BRAF inhibition in melanoma results in paradoxical MAPK signalling and accelerated growth of cutaneous squamous-cell carcinomas and keratoacanthomas; many of these lesions harbour RAS mutations. For both these reasons, the combination of BRAF and MEK inhibitors was compelling; the combination of the BRAF inhibitor, dabrafenib, and the MEK inhibitor, trametinib, in metastatic melanoma resulted in improved response rates and PFS, with a reduction in the rate of proliferative cutaneous lesions (Flaherty et al, 2012) . Pre-clinical data in cHCL with BRAF V600E mutation suggests that, in the setting of stromal co-culture (re-capitulating the BM microenvironment), dual BRAF-MEK inhibition produces greater ERK dephosphorylation and apoptosis in cHCL cells than treatment with either agent alone (Pettirossi et al, 2015) . A phase II study with dabrafenib and trametinib in BRAF V600E-mutated rare cancers (including cHCL) is accruing (NCT02034110).
Antibody-drug conjugates
In addition to CD20, which is highly expressed on the surface of HCL, and has been successfully targeted with rituximab, HCL has high expression of CD22 (Foucar et al, 2008) . CD22 is an excellent target for antigen for antibodydrug conjugates (ADCs), given its expression on normal cells is limited to the B-lymphocyte lineage (Clark, 1993) and it is rapidly internalized after antibody binding, delivering the ADC's payload to the intracellular compartment. Kreitman et al (2001) developed a recombinant antibodydrug toxin, known as BL22, consisting of the variable domain (Fv) of a CD22 monoclonal antibody, conjugated to a fragment of pseudomonas exotoxin, which contains domains responsible for cell death, but not for cell binding 
Bruton tyrosine kinase inhibitors
BTK is a key protein in transduction of signals via the B-cell receptor, which plays a key role in the survival of normal and malignant B-cells (Honigberg et al, 2010) . BTK inhibition has been dramatically successful in CLL (Byrd et al, 2013 (Byrd et al, , 2016 Burger et al, 2015) . BTK is constitutively expressed and is phosphorylated in response to BCR triggering in HCL cells (Sivina et al, 2014) . BTK phosphorylation can be abrogated by ibrutinib, which also reduced cell viability in vitro. Of note, patients with BRAF V600E mutation had greater pBTK levels at baseline, but were less sensitive than cHCL patients without BRAF mutations or those with HCL-v (Sivina et al, 2014) . A multi-centre phase II study in patients with relapsed cHCL or HCL-v is ongoing (NCT01841723). Although it remains to be seen whether these in vitro results are recapitulated in the clinic, the fact that patients without BRAF mutation are more sensitive in vitro to BTK inhibition is intriguing, as they generally have more aggressive disease and fewer therapeutic options.
Bendamustine and rituximab
Bendamustine is approved in both CLL and non-Hodgkin Lymphoma and has properties of both an alkylating agent and a purine analogue (Rummel & Gregory, 2011) . A pilot study of 6 cycles of bendamustine (70-90 mg/m 2 ) plus two infusions of rituximab 375 mg/m 2 per cycle, in multiplyrelapsed cHCL demonstrated an overall response rate of 100%, with 50-67% CR (Burotto et al, 2013) . Notably, 50% of all patients achieved MRD-negativity. The CRs were durable, with all patients remaining relapse-free at a median follow-up of 31 months. Toxicity (predominantly myelosuppression and lymphopenia) was manageable.
Our current approach to cHCL
Diagnosis
In addition to routine complete blood count (CBC) and biochemistries, we perform the following testing at diagnosis:
1 BM aspirate and biopsy. The biopsy is essential, given that the disease is often associated with a 'dry tap' due to the associated fibrosis. 2 Flow cytometry and/or immunohistochemistry. Confirmation of the diagnosis of cHCL is made on the basis of typical immunophenotypic features, assessed by MFC from either BM or blood (see Table I ) and/or demonstration of characteristic immunohistochemical markers (DBA.44 or Annexin A1). 3 BRAF V600E mutational analysis. In view of the prognostic importance of BRAF V600E mutation and the availability of targeted therapeutic strategies, we view testing for this mutation to be essential at diagnosis. We perform targeted, Sanger sequencing for this mutation, which has a sensitivity of approximately 20%. The low sensitivity may be problematic in paucicellular, blooddilute specimens and we will therefore soon be moving to a much more sensitive next-generation sequencing based assay (K. Patel, M.D. Anderson Cancer Center, Department of Hematopathology, Houston, TX, USA, personal communication). In the interim, we perform immunohistochemistry for BRAF V600E in patients who are negative for the mutation by sequencing. The VE1 antibody clone is highly mutation-specific and has been demonstrated in the BM in patients with cHCL (Andrulis et al, 2012). 4 IGHV sequencing. We perform IGHV sequencing and somatic hypermutation analysis in all patients; this is not essential, but we find it to be useful, given the prognostic importance of demonstrating IGHV4-34 gene utilization and unmutated IGHV. 5 Baseline and follow-up sCD25 (interleukin-2 receptor) levels as a marker of disease burden.
Imaging does not play a role in the routine diagnostic work-up of HCL, as it is not required for the diagnosis, staging or monitoring of the disease response. However, it may be useful in specific circumstances (e.g. evaluation of rare cases of suspected extra-medullary disease).
Initial therapy
At our centre, where possible, treatment-na€ ıve patients with cHCL or HCL-v are treated with cladribine + sequential rituximab on an ongoing phase II trial. It would also be reasonable to use either cladribine or pentostatin monotherapy in the majority of patients as first line therapy. However, we believe that use of combination therapy is particularly important for patients with HCL-v and cHCL patients with IGHV4-34, BRAF negativity and unmutated IGHV, who have a higher risk for disease relapse.
Response assessment
We perform the following testing for response assessment:
1 CBC, to determine recovery of haematopoiesis. 2 BM aspirate and biopsy. 3 Multi-parameter flow cytometry from BM to quantify MRD. 4 Quantification of sCD25 (serum IL2RA).
Treatment at first relapse
If patients have previously not received the combination of cladribine plus rituximab, regardless of first remission duration or achieved a first remission duration after cladribine plus rituximab of at least 5 years after, we treat with cladribine plus rituximab. If patients have had a short remission after first line cladribine plus rituximab, we enrol them on a clinical trial of a novel agent.
Consolidation therapy
No data exists concerning the role of consolidation therapy in patients who fail to achieve CR with initial therapy. Our own practice is to give rituximab consolidation after initial treatment with cladribine wherever possible, given the association with superior outcomes in relapsed patients and the ability of rituximab to convert over 2/3 of patients who are MRD-positive to MRD-negative post-cladribine. However, where possible, this should be performed as part of a clinical trial.
Treatment at subsequent relapse
At subsequent relapse, we generally recommend enrolment in a clinical trial of a novel agent. However, cladribine + rituximab would be reasonable, if patients have never previously received combination therapy.
Choice of novel therapeutic agents in relapsed patients
There is no data to guide this choice. In patients with BRAF V600E, we generally treat with a BRAF inhibitor AE MEK inhibitor or a CD22-targeted ADC. For patients without BRAF V600E, we treat with ibrutinib or a CD22-targeted ADC, all of which are available on current clinical trials. Bendamustine plus rituximab could also be considered, particularly in purine analogue-refractory patients who have not previously received rituximab and if other novel agents were unavailable. Given the limited experience with this combination, despite its widespread use in other haematological malignancies, it would be preferable to use this regimen in the setting of a clinical trial.
Conclusion
In summary, while dramatic improvements in the treatment of hairy cell leukaemia have occurred in the past three decades and outcomes are generally excellent, the disease remains incurable and sequential therapies are associated with cumulative toxicity. Further optimisation of treatment, which integrates novel therapies, in both treatment-na€ ıve and relapsed patients, is required to maximise remission duration and ideally, to cure the disease. The prolonged DFS achieved with purine analogues creates challenges in comparing the effectiveness of novel strategies with standard therapy. These studies will require multicentre collaborative efforts and alternative methods of assessing efficacy, such as the use of standardised and sensitive MRD analysis as a surrogate marker for PFS.
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